Eevia Health Plc ("Eevia" or "The Company") is welcoming Tuomas Jylhä as interim Chief Financial Officer. Gabriella Beni has decided to leave the Company for personal reasons to focus on private matters. Eevia wishes her the very best in her future endeavors. Tuomas Jylhä will take over the position on July 26th.
Tuomas Jylhä comes from the position of Financial Manager at Rantalainen, a financial administration services firm, with over 1,100 experts in 50 locations in Finland. Tuomas Jylhä has a Master's degree in economics and a professional background in banking and auditing. He is based in the same town where Eevia Health is headquartered - Seinäjoki. Tuomas is part of the team in Rantalainen that provides interim CFO services to clients across Finland.
The company has initiated a search for a permanent CFO and expects to announce a full-time CFO by the end of the year.
"We are very pleased to welcome Tuomas Jylhä as Interim CFO of Eevia. Eevia and Rantalainen have cooperated closely since Eevia was founded in 2017 and Rantalainen has provided competent financial administration, accounting, and payroll services to Eevia since then. As our Interim CFO, Tuomas will strengthen the cooperation on financial administration with Rantalainen. He will streamline the reporting and finance function in the Company going forward, with a focus on controlling and profitability management", comments Stein Ulve, CEO of Eevia Health Plc.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.
Eevia Health Plc, ("Eevia" or "The Company"), has re-established its Kosher certification. The Jewish Community of Helsinki has validated Eevia's Kosherization and certified the Kosher and Parve status of the company products.
Eevia Health Plc ("Eevia" or "The Company") is releasing its quarterly financial report for the third quarter of 2022.
Eevia Health Plc ("Eevia" och "the Company") announces today the outcome of the Rights Issue, whose subscription period ended on November 15, 2022, where a total of 14 376 015 shares, corresponding to 100 percent of the offered shares, have been allocated. 9 233 685 shares (64 percent) were subscribed with subscription rights, and 5 142 330 shares (36 percent) were subscribed without subscription rights, corresponding to 100 percent of the Rights Issue. Through the Rights Issue, the Company will raise proceeds of approximately SEK 21.6 million before deducting costs related to the Rights Issue. No guaranteed commitments have been utilized.
To timely secure raw materials for its recent order intake of large quantities of bilberry products, Eevia Health Plc ("Eevia" or "The Company") has secured a short-term loan of NOK 2 million from its largest shareholder, Betulum AS (Norway).
Following a successful exhibition at the Supply Side West trade show in Las Vegas, US, last week, Eevia Health received a start order for its new cognitive health product, the Feno-Cerasus™, for SEK 223k. The new product was launched last week and is a standardized anthocyanin extract from tart cherry (Prunus Cerasus). Eevia Health focuses on the cognitive effects of the latest product, including sleep quality and quantity, memory, stress, and cortisol levels.
Following a successful exhibition at the Supply Side West trade show in Las Vegas, US, last week, Eevia Health ("Eevia" or "The Company") received an order for the Feno-Sambucus™ equaling a revenue of SEK 34.4 million. The order is a new contractual volume section related to a five-year Sales Agreement with a US brand owner. The new section has adjusted prices and terms.
Eevia Health has developed a new plant extract with product benefits for cognitive health and improved sleep. The new product, Feno-Cerasus™, is launched today at a major trade show in Las Vegas, US, the Supply Side West. The new ingredient is a standardized anthocyanin extract from tart cherry (Prunus Cerasus). Eevia Health focuses on the cognitive effects of the new products, including sleep quality and quantity, memory, as well as stress, and cortisol levels.
Eevia Health is presenting its branded ingredients at a major trade show for the nutraceutical industry, SupplySide West, which takes place in Las Vegas, USA this week. This trade show is co-organized with Food ingredients North America and is the premier gathering of health & nutrition professionals bringing together buyers and suppliers from throughout the industry. SupplySide events are all about the science and strategy around the development of products driving the global business economy.
The Board of Directors of Eevia Health Plc ("Eevia" or the "Company") has today decided on a rights issue with preferential rights for Eevia's existing shareholders ("Rights Issue"). The target amount is approximately SEK 21.6 million. The proceeds shall primarily finance sales and marketing efforts and increase working capital. About 82 percent of the Rights Issue is covered by subscription and guarantee commitments.